Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, January 27, 2015
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
First Contracting Human Muscle Grown in Laboratory
Researchers at Duke University report the first lab-grown, contracting human muscle, which could revolutionize drug discovery and personalized medicine.
Antriabio Announces Completion Of PK/PD Studies Of AB101
AB101 positioned to be the first once-weekly basal insulin for diabetes patients.
Anti-Diabetic Drug Springs New Hope for Tuberculosis Patients
Drug for treating diabetes can double up as adjunct treatment for tuberculosis.
A Poisonous Cure
Toxic fungi may hold the secrets to tackling deadly diseases.
Antibiotic Resistance Threatens Future of Modern Medicine
Overuse and misuse of antibiotics, one of the key contributors to antimicrobial resistance (AMR).
Bacterial Toxin Targets Discovered
Understanding how bacterial toxins target human cells is set to have major implications for the development of novel drugs.
Proteomics for Systems Toxicology
MS-based proteomics is maturing into a robust technology for the measurement of proteome-wide exposure effects.
Molecular Event Mapping Opens Door to more in silico Tests
It is hoped that this new approach to mapping and predicting the impact of chemical compounds in the body could reduce the need for toxicity tests in animals.
Protein-engineered Cages Aid Studies of Cell Functions
The Cages, from researchers at Tokyo Institute of Technology, to deliver an important signalling molecule, carbon monoxide, into cells.
Wallet-Sized Labs The Next Big Thing
RMIT researchers are developing inexpensive, portable toxicology laboratories so small you could fit them in your wallet.
Scroll Up
Scroll Down
Return
Novel Recombinant Peptide Toxin Fusion Proteins as Potential Therapeutics for the Treatment of Autoimmune Disease
Hung Nguyen, Principal Scientist, Amgen, speaking at Ion Channel Targets 2008
Date Posted: Friday, June 19, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



FDA Approves Amgen's XGEVA™ for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors
The approval is based on largest clinical program ever conducted in patients with bone metastases.
Monday, November 22, 2010
FDA Approves Nplate™ for Long-Term Treatment of Adult Chronic ITP
Amgen to launch Nplate™ NEXUS program to provide treatment access and patient support programs.
Monday, August 25, 2008
 
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn